Literature DB >> 27591498

Myxofibrosarcoma.

Christina L Roland1, Wei-Lien Wang2, Alexander J Lazar2, Keila E Torres3.   

Abstract

Myxofibrosarcoma is a unique subtype of soft tissue sarcoma with a locally infiltrative behavior. High-quality MRI imaging is critical for preoperative planning. Wide surgical resection with a 2 cm soft tissue margin is the mainstay of treatment and can require complex vascular and plastic surgery reconstruction. Local recurrence is common, and a subset of patients with higher-grade lesions will develop distant metastases. Radiation may be beneficial in reducing local recurrence.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRI; Myxofibrosarcoma; Recurrence; Surgery

Mesh:

Year:  2016        PMID: 27591498     DOI: 10.1016/j.soc.2016.05.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  19 in total

1.  High-grade myxofibrosarcoma of the abdominal wall.

Authors:  Richard Antbring; Sam G Parker; Jeffrey T Lordan; Alastair Cj Windsor
Journal:  BMJ Case Rep       Date:  2017-06-02

2.  Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report.

Authors:  Jason P Lambden; Max F Kelsten; Brian C Schulte; Susan Abbinanti; John P Hayes; Victoria Villaflor; Mark Agulnik
Journal:  Oncologist       Date:  2021-03-08

3.  Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.

Authors:  Atsushi Yamashita; Yoshiyuki Suehara; Takuo Hayashi; Tatsuya Takagi; Daisuke Kubota; Keita Sasa; Nobuhiko Hasegawa; Muneaki Ishijima; Takashi Yao; Tsuyoshi Saito
Journal:  Virchows Arch       Date:  2022-06-15       Impact factor: 4.535

4.  ASO Author Reflections: VAC Dressing in Staging Myxofibrosarcoma Resection in the Extremities: Is it Safe?

Authors:  Santiago Lozano-Calderon
Journal:  Ann Surg Oncol       Date:  2021-06-28       Impact factor: 5.344

5.  RSF1 requires CEBP/β and hSNF2H to promote IL-1β-mediated angiogenesis: the clinical and therapeutic relevance of RSF1 overexpression and amplification in myxofibrosarcomas.

Authors:  Chien-Feng Li; Ti-Chen Chan; Cheng-I Wang; Fu-Min Fang; Po-Chun Lin; Shih-Chen Yu; Hsuan-Ying Huang
Journal:  Angiogenesis       Date:  2021-01-26       Impact factor: 10.658

6.  Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report.

Authors:  Yi Luo; Li Min; Yong Zhou; Fan Tang; Minxun Lu; Hongmei Xie; Yitian Wang; Hong Duan; Wenli Zhang; Chongqi Tu
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

Review 7.  Multiple recurrent myxofibrosarcoma of the orbit: case report and review of the literature.

Authors:  Baixue Du; Xin He; Yujiao Wang; Weimin He
Journal:  BMC Ophthalmol       Date:  2020-07-06       Impact factor: 2.209

Review 8.  CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.

Authors:  Jordan L Kohlmeyer; David J Gordon; Munir R Tanas; Varun Monga; Rebecca D Dodd; Dawn E Quelle
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

9.  Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma.

Authors:  Vittoria Colia; Marco Fiore; Salvatore Provenzano; Elena Fumagalli; Rossella Bertulli; Carlo Morosi; Angelo P Dei Tos; Marta Barisella; Alessandro Gronchi; Paolo G Casali; Roberta Sanfilippo
Journal:  Clin Sarcoma Res       Date:  2017-08-22

10.  Myxofibrosarcoma of the mandible: a case report and review of the literature.

Authors:  Zhengqiang Li; Xianwen Liu; Quanyin Zhang; Jie Zhang; Mingyi Huang; Shuguang Liu
Journal:  BMC Oral Health       Date:  2020-04-16       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.